ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Metavention Completes U.S. Enrollment in Groundbreaking Feasibility Study to Treat Type 2 Diabetes
January 06, 2022Metavention, Inc. announces the completion of enrollment in the DeLIVER U.S. Study (NCT04285554), to evaluate the safety of sympathetic denervation of the liver using its new Integrated Radio Frequency (iRF) Denervation System. -
Metavention Initiates Trial for Novel Treatment of Type 2 Diabetes
February 20, 2021Metavention announced the initiation of an U.S. Food and Drug Administration (FDA) approved clinical investigation, DeLIVER, for the Company's intravascular iRF Denervation System to determine safety in patients with type 2 diabetes (T2D).
Pharma Sources Insight January 2025
